EUVIMEDOdkrijte EUVIMED
EUVIMED · CrossrefJournal

Breast Cancer Research and Treatment

ISSN 0167-6806 · Springer Science and Business Media LLC

Latest articles

  1. Brain as a site of first recurrence after adjuvant therapy for early breast cancer: mining the hellenic cooperative oncology group database-The BRACE study

    Evangelia Razis, Kyriaki Papadopoulou, Nikolaos Korfiatis, Christos Christodoulou, Helen P. Kourea, Anna Goussia, Olympia Tzaida, Anna Batistatou, Andreas Mamilos, Christos Markopoulos, Vasileios Venizelos, Grigorios Xepapadakis, Pantelis Skarlos, George Pentheroudakis, Dimitrios Pectasides, Angelos Koutras, Athina Christopoulou, Amanda Psyrri, Helen Gogas, Flora Zagouri, George Fountzilas

    Published: 2026-11DOI: 10.1007/s10549-026-08085-2

  2. Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA®) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India

    Ayesha Mahajan, Soumya Surath Panda, Lalatendu Moharana, M.V. Chandrakanth, Vivek Agarwala, Rupam Manna, S.V. Saju, Susan Honey Raju, Prasanth Ganesan, Gomathi Shankar, Ashwin Oommen Phillip, Sunu Lazar Cyriac, Anil Jose, P. Unnikrishnan, Kanu Priya Bhatia, Amit Sehrawat, Deepak Sundriyal, Himani Dhanai, Lipsita Samantaray, Swati Sucharita Mohanty, Biswajit Dubashi

    Published: 2026-11DOI: 10.1007/s10549-026-08114-0

  3. Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD

    Norikazu Masuda, Shigehira Saji, Yasuyuki Kojima, Masahiro Kitada, Hiroshi Tada, Tsutomu Iwasa, Kei Koizumi, Tsuguo Iwatani, Yasuaki Sagara, Takashi Kuwayama, Masafumi Shimoda, Tatsunari Sasada, Koichiro Tsugawa, Yoshihiro Kawaguchi, Akihiko Shimomura, Takuhiro Yamaguchi, Hiroki Hasegawa, Shun Osaka, Satoshi Morita, Toshinari Yamashita

    Published: 2026-07DOI: 10.1007/s10549-026-08004-5

  4. EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study

    Diogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, Bernardo Pereira, Leonor Vasconcelos de Matos, Leonor Fernandes, Elsa Campôa, Guilherme Nader-Marta, Michel Moreau, Donatienne Taylor, Francois P. Duhoux, Pedro Simões, Ana Rita Garcia, Vanessa Patel, Caterina Confente, Diogo Alpuim Costa, José Pereira, Catarina Santos, Marianne Paesmans, Frederico Sarmento, Teresa Gantes Padrão, Diana Simão, Daniel Bandarra, Berta Sousa, Margarida Brito, Andrea Gombos, Lieveke Ameye, Evandro de Azambuja

    Published: 2026-07DOI: 10.1007/s10549-026-08012-5

Volumes

2026 · 3002025 · 3552024 · 3732023 · 3352022 · 3682021 · 4742020 · 4752019 · 4732018 · 4742017 · 4532016 · 3702015 · 4382014 · 4262013 · 4622012 · 6882011 · 6442010 · 5962009 · 4432008 · 3542007 · 2832006 · 2512005 · 2452004 · 2032003 · 2672002 · 2162001 · 1842000 · 1621999 · 1751998 · 1791997 · 1361996 · 1661995 · 1251994 · 1421993 · 1411992 · 1101991 · 1311990 · 891989 · 681988 · 791987 · 69

Znanje, ki ustreza vašemu delu.

Od brezplačnega začetka in osebnega iskanja literature do celotnega paketa Research Suite.

Ogled tarif →

Ali so vključena vsa polna besedila založnikov?

Ne. Bibliografski zapisi, povzetki in celotna besedila so različne vsebine. Ali je celotno besedilo na voljo, je odvisno od vira, odprtega dostopa in vaših obstoječih licenc. Paket EUVIMED ne nadomešča dodatnih pravic založnikov.